Recombinant Equine IL28B Protein
Cat.No. : | IL28B-4370E |
Product Overview : | Recombinant Equine IL28B Protein (170aa) was expressed in yeast. |
Availability | January 14, 2025 |
Unit | |
Price | |
Qty |
- Specification
- Gene Information
- Related Products
- Download
Source : | Yeast |
Species : | Equine |
Form : | Lyophilized |
Molecular Mass : | 19.0 kDa |
Protein length : | 170aa |
AA sequence : | GPVPTSKPAT TQRSCDIGRF KSLSPSELEA FKKAKDALEN SLENWTCRSP VFPTTWDLRQ LQVWERPVAL EAELALTLKI LAMVADSSLA DILDRPLHTL RHIHSELQAC VPARPTAGPG PRGRLHQWLR QLHEVQKKES WGCLEASVTF NLFRLLTRDL NCVASGDLCL (170) |
Purity : | >95% as visualized by SDS-PAGE analysis. |
Applications : | This endotoxin-free recombinant protein can be used in cell culture, ELISA Standard, and as a Western Blot Control. |
Storage : | Store at -20 centigrade. |
Tag : | Non |
Gene Name : | IL28B interferon lambda-1 [ Equus caballus (horse) ] |
Official Symbol : | IL28B |
Synonyms : | interferon lambda-1; IL28B |
Gene ID : | 100146825 |
mRNA Refseq : | XM_014732932.1 |
Protein Refseq : | XP_014588418.1 |
Products Types
Related Gene
Not For Human Consumption!
Inquiry
- Reviews
- Q&As
Customer Reviews (3)
Write a reviewActivity retention time is very long and can be maintained for a long time.
High cost performance and low preparation cost.
It has a wide range of applications and can be used in various biological experiments.
Q&As (6)
Ask a questionIL28B has achieved remarkable results in the treatment of hepatitis C. The study found that patients with a specific genotype, which is related to IL28B, were better able to benefit from treatment with the hepatitis drug interferon. Therefore, the combination of IL28B with other drugs can improve the efficacy.
IL28B can regulate the immune response of cells and promote the occurrence of insulin-dependent cytotoxicity mediated by NK cells, thus playing an antiviral role.
The purification methods of IL28B include ion exchange, gel filtration, affinity chromatography, countercurrent chromatography, etc.
The dose of treatment with IL28B varies depending on the patient. When treating hepatitis C, the dose is usually given once a week, 500ug or another dose.
The adverse reactions of IL28B include fever, headache, fatigue, muscle aches, nausea, diarrhea and other symptoms, and in severe cases, allergic reactions and liver damage.
IL28B will have a certain impact on the function of other organs of the body, such as the liver, kidneys, etc., but the use of normal doses in clinical practice is generally safe.
Ask a Question for All IL28B Products
Required fields are marked with *
My Review for All IL28B Products
Required fields are marked with *
Inquiry Basket